Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28703128 | 0.84 | MAOB (0.47) | MAOBNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL5133901 | 0.83 | MAOB (0.46) | MAOBNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL29797867 | 0.76 | NPC1 (0.56) | MAOBNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL15197232 | 0.75 | SMN1; SMN2 (0.47) | MAOBRAB9ASMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL8392453 | 0.74 | MAOB (0.57) | MAOBNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL14757597 | 0.74 | MAOB (0.57) | MAOBNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL28716485 | 0.73 | MAOB (0.46) | MAOBNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL6834190 | 0.73 | MAOB (0.56) | MAOBNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL3926765 | 0.73 | MAOB (0.56) | MAOBNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL257536 | 0.72 | SMN1; SMN2 (0.44) | MAOBNPC1RAB9ASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442800-B2 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2008-10-28 | — | — | US | claimed |
| CN-101184711-A | Nucleophilic heterocyclic carbene derivatives of pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2008-05-21 | — | — | CN | claimed |
| US-20060287544-A1 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2006-12-21 | — | — | US | claimed |
| US-7442800-B2 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442800-B2 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2008-10-28 | — | — | US | disclosed |
| US-20060287544-A1 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287544-A1 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | NDC1, DDC, PDCD1LG2 | MAOB 665/4885NPC1 3414/4885RAB9A 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.